Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 30 June 2026

CHF
169
million
Cathay Biotech
(Fair value CHF 168.96 million / 7.7% of total assets)
more
CHF
92
million
Dren Bio
(Fair value CHF 92.3 million / 4.2% of total assets)
more
Swixx BioPharma
CHF
78
million
(Fair value CHF 78.0 million / 3.6% of total assets)
more
Argenx
CHF
75
million
(Fair value 75.0 million / 3.6% of total assets)
more
ArriVent BioPharma
CHF
72
million
(Fair value CHF 71.6 million / 3.3% of total assets)
more
Neurelis
CHF
67
million
(Fair value CHF 67.3 million / 3.1% of net assets)
more
CHF
63
million
Harmony Biosciences
(Fair value 63.2 million / 2.9% of total assets)
more
CHF
53
million
Zymeworks
(Fair value CHF 53.3 million / 2.4 of net assets)
more
Natera
CHF
53
million
(Fair value 52.7 million / 2.6% of total assets)
more
Curevo Vaccine
CHF
43
million
(Fair value CHF 42.6 million / 1.9% of total assets)
more